Dr. Lindenmayer Replies

View This PDF

NB: This article is only available as a PDF.

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: In his letter to the editor, Dr. Murphy opines against the use of a first-generation antipsychotic as a comparator in our study,1 stating that “the mean dose of haloperidol used (17.11 mg) invariably induces secondary negative symptoms.” However, there is little evidence that haloperidol systematically induces secondary negative symptoms. In fact, 2 recent studies2,3 comparing the effects of olanzapine, a secondgeneration antipsychotic with a very benign extrapyramidal symptom profile, with haloperidol at doses similar to those used in our study combined with benztropine found no significant differences for positive or negative symptoms in schizophrenia between the 2 antipsychotics. ​

J Clin Psychiatry 2008;69(1):164-165